• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比索洛尔与伊伐布雷定联合治疗对合并慢性阻塞性肺疾病的缺血性心脏病患者的疗效——24小时动态心电图监测参数评估

[Efficacy of therapy with bisoprolol and ivabradine in patients with ischemic heart disease combined with chronic obstructive pulmonary disease assessment of parameters of 24-hour ECG monitoring].

作者信息

Grigor'eva N Iu

出版信息

Kardiologiia. 2009;49(7-8):38-41.

PMID:19656105
Abstract

Effect of therapy with 1-adrenoblocker bisoprolol and inhibitor of If channels ivabradine on parameters of 24-hour ECG monitoring (24hECGM) was studied in 64 patients with ischemic heart disease (stable angina) and chronic obstructive pulmonary disease (COPD). At the first stage all patients received bisoprolol. Parameters of external respiration function (ERF) and 24h ECG were registered before and after 4 months of bisoprolol administration. At stage 2 indications were determined for inclusion of ivabradine in the treatment scheme. At the background of therapy with bisoprolol we obtained significant lowering of heart rate (HR) both during day and night, as well as significant diminution of magnitude and duration of ischemic ST depression. In 44% of patients target HR range was not achieved. This conditioned the necessity to administer ivabradine. Therapy of patients with stable angina and concomitant COPD should begin with cardioselective -adrenoblockers (bisoprolol). Incorporation of inhibitor of If channels ivabradine in the treatment scheme is indicated if during treatment with -adrenoblockers average 24 hour HR according to data of 24hECGM exceeds 70 beats/min and deterioration of bronchial conductance according to ERF data occurs.

摘要

在64例缺血性心脏病(稳定型心绞痛)合并慢性阻塞性肺疾病(COPD)的患者中,研究了1-肾上腺素能阻滞剂比索洛尔和If通道抑制剂伊伐布雷定治疗对24小时心电图监测(24hECGM)参数的影响。在第一阶段,所有患者均接受比索洛尔治疗。在给予比索洛尔4个月前后,记录患者的外呼吸功能(ERF)参数和24h心电图。在第二阶段,确定将伊伐布雷定纳入治疗方案的指征。在比索洛尔治疗的基础上,我们观察到患者白天和夜间的心率(HR)均显著降低,缺血性ST段压低的幅度和持续时间也显著缩短。44%的患者未达到目标心率范围。这使得有必要给予伊伐布雷定。对于稳定型心绞痛合并COPD的患者,治疗应从心脏选择性β-肾上腺素能阻滞剂(比索洛尔)开始。如果根据24hECGM数据,在使用β-肾上腺素能阻滞剂治疗期间患者24小时平均心率超过70次/分钟,且根据ERF数据显示支气管传导功能恶化,则表明在治疗方案中应加入If通道抑制剂伊伐布雷定。

相似文献

1
[Efficacy of therapy with bisoprolol and ivabradine in patients with ischemic heart disease combined with chronic obstructive pulmonary disease assessment of parameters of 24-hour ECG monitoring].比索洛尔与伊伐布雷定联合治疗对合并慢性阻塞性肺疾病的缺血性心脏病患者的疗效——24小时动态心电图监测参数评估
Kardiologiia. 2009;49(7-8):38-41.
2
[Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease].[心脏选择性β1-肾上腺素能阻滞剂比索洛尔治疗慢性阻塞性肺疾病合并缺血性心脏病患者的疗效]
Ter Arkh. 2007;79(3):25-9.
3
[The efficacy and safety of the combination of β-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease].β受体阻滞剂比索洛尔与If抑制剂伊伐布雷定联合应用于稳定型心绞痛合并慢性阻塞性肺疾病患者的疗效与安全性
Kardiologiia. 2010;50(10):22-6.
4
Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina.在稳定性心绞痛患者中,伊伐布雷定联合β受体阻滞剂与β受体阻滞剂滴定治疗的疗效比较。
Cardiovasc Drugs Ther. 2011 Dec;25(6):531-7. doi: 10.1007/s10557-011-6327-3.
5
[Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease].[β1肾上腺素能阻滞剂比索洛尔对稳定型心绞痛合并慢性阻塞性肺疾病患者内皮功能障碍的影响]
Ter Arkh. 2009;81(3):28-31.
6
[Clinical efficacy of ivabradine in patients with ischemic heart disease in combination with chronic obstructive pulmonary disease].
Kardiologiia. 2008;48(3):13-9.
7
[Effect of the I(f) channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period].
Ter Arkh. 2010;82(3):23-5.
8
[Clinical efficiency of ivabradine in patients with cardiorespiratory pathology].
Klin Med (Mosk). 2008;86(5):44-54.
9
[The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris].
Georgian Med News. 2015 Mar(240):25-8.
10
Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.在伴有气道阻塞性疾病的患者中,伊伐布雷定的降心率疗效和呼吸安全性:一项随机、双盲、安慰剂对照、交叉研究。
Am J Cardiovasc Drugs. 2012 Jun 1;12(3):179-88. doi: 10.2165/11597400-000000000-00000.

引用本文的文献

1
Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.伊伐布雷定:心血管疾病及其他新适应症的证据与当前作用
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20.